Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 6.6% - Here's What Happened

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) shares traded down 6.6% on Thursday . The company traded as low as $23.24 and last traded at $22.93. 44,313 shares changed hands during trading, a decline of 68% from the average session volume of 139,864 shares. The stock had previously closed at $24.56.

Analyst Ratings Changes

Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research note on Thursday, January 2nd.

Pulse Biosciences Stock Up 2.7 %

The stock has a fifty day moving average of $18.86 and a 200 day moving average of $17.95.

Insider Activity at Pulse Biosciences

In other news, CEO Burke Thomas Barrett sold 50,000 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert W. Duggan purchased 55,256 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average cost of $17.18 per share, with a total value of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares in the company, valued at $727,207,358.06. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. 71.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pulse Biosciences

Several large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock valued at $2,598,000 after buying an additional 97,565 shares during the last quarter. State Street Corp lifted its position in shares of Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company's stock worth $8,092,000 after purchasing an additional 69,696 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Pulse Biosciences during the third quarter valued at $588,000. Geode Capital Management LLC grew its holdings in shares of Pulse Biosciences by 7.8% in the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock worth $8,020,000 after purchasing an additional 33,200 shares during the last quarter. Finally, Barclays PLC increased its stake in Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company's stock worth $530,000 after buying an additional 23,738 shares during the period. Institutional investors own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.